IMUX — Immunic Cashflow Statement
0.000.00%
Last trade - 00:00- $109.90m
- $63.22m
Annual cashflow statement for Immunic, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -34.9 | -44 | -92.9 | -120 | -93.6 |
| Depreciation | |||||
| Non-Cash Items | 7.7 | 0.219 | 18.9 | 45.7 | 7.63 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.36 | -2.37 | -9.28 | 9.53 | 15 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -28.5 | -46.1 | -83.2 | -65.1 | -70.8 |
| Capital Expenditures | -0.055 | -0.146 | -0.067 | -0.112 | -0.334 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 10.6 | 0 | — | -9.63 | 9.8 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 10.5 | -0.146 | -0.067 | -9.74 | 9.46 |
| Financing Cash Flow Items | -0.27 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 34.9 | 144 | 42.8 | 95.8 | 1.03 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 16.3 | 98.1 | -40.6 | 19.9 | -60.1 |